Ultrasound-Propelled Liposome Circumvention and siRNA Silencing Reverse BRAF Mutation-Arised Cancer Resistance to Trametinib

Jie Chen,Chao Fang,Cheng Chang,Kai Wang,Haizhen Jin,Tong Xu,Jingwei Hu,Weihua Wu,E Shen,Kun Zhang
DOI: https://doi.org/10.1016/j.colsurfb.2023.113710
IF: 5.999
2023-12-17
Colloids and Surfaces B Biointerfaces
Abstract:BRAF-V600E mutation is regarded as the source of lung cancer resistance to trametinib (Tr), and no solution available for completely addressing this intractable resistance has emerged yet. Herein, the combination of ultrasonic (US) propelled folic acid (FA)-modified liposomes strategy and BRAF-driven gene silencing programme is proposed to effectively reverse Tr's resistance to lung cancer. Meanwhile, the prepared cationic nanoliposomes can assist Tr drug and BRAF siRNA to escape lysosome disposal, thereby avoiding Tr drug pumping out or siRNA degradation. More significantly, loaded BRAF siRNA is designed to silence BRAF-V600E mutation genes via modulating BRAF-ERK-pathway and remarkably reverse the PC9R resistance to Tr. Systematic experiments validate that these cooperatively sensitize PC9R cells to Tr and shrink resistant NSCLC in vivo, especially after combining with FA-mediated targeting and US-enhanced permeability that permits more intratumoral accumulations of Tr. Such a biocompatible targeting drug-resistance liberation agent and its underlying design strategy lay a foundation avenue to completely reverse tumor resistance, which is preferable to treat BRAF mutation-arised resistance of various tumors, holding high clinical translation potentials.
materials science, biomaterials,biophysics,chemistry, physical
What problem does this paper attempt to address?